TickerFacts.

Liquidia Corp (LQDA): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$283.19M
As of 2025-12-31
$326.80M
As of 2026-06-30
2019-12-31: $33.89M2020-12-31: $28.45M2021-12-31: $28.46M2022-12-31: $38.78M2023-12-31: $71.04M2024-12-31: $150.94M2025-12-31: $283.19M$283.19M
2019-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$283.19M+87.6%2026-03-05, Balance as of period end
2024-12-31$150.94Mn/c2026-03-05, Balance as of period end
2023-12-31$71.04M+83.2%2025-03-19, Balance as of period end
2022-12-31$38.78M+36.2%2024-03-13, Balance as of period end
2021-12-31$28.46M+0.1%2023-03-20, Balance as of period end
2020-12-31$28.45M-16.1%2022-03-17, Balance as of period end
2019-12-31$33.89Mn/a2021-03-25, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Liquidia Corp (LQDA)2025-12-31$283.19M+87.6%
Heron Therapeutics, Inc. (HRTX)2025-12-31$241.54M-9.5%
Macrogenics Inc (MGNX)2025-12-31$201.25M+38.2%
Elite Pharmaceuticals Inc (ELTP)2026-03-31$39.41M-8.1%
Karyopharm Therapeutics Inc. (KPTI)2025-12-31$401.34M+14.5%
Syndax Pharmaceuticals Inc (SNDX)2025-12-31$465.08M+6.5%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$697.32M+10.4%
Cryoport, Inc. (CYRX)2025-12-31$262.35M-13.0%
Lifevantage Corp (LFVN)2026-06-30$28.52M-23.6%

Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗